

3 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| CONTINENTAL PARTNERS LP | November 1999 | Indefinite | $180M | 127 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
3 partners are named across this firm’s filings, 3 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| David O'Neill | Slowing | Developer tools & infrastructure, Biotech & pharma, Food & agriculture | 4 |
Classified sectors of Continental Partners’s own portfolio companies, based on 5 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Continental Partners’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Continental Healthcare Fund QP | 5 | APIContext, APImetrics, CTRL Therapeutics USA, LIONHEART CIDER, Onramp Funds |
A shared board seat: a company where filings name a Continental Partners partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.
| 1 |
| David Purcell | Quiet | Fintech | 1 | 0 |
| Gregory Ramenofsky | Quiet | None listed | 0 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.